JP2022550458A5 - - Google Patents

Info

Publication number
JP2022550458A5
JP2022550458A5 JP2022520471A JP2022520471A JP2022550458A5 JP 2022550458 A5 JP2022550458 A5 JP 2022550458A5 JP 2022520471 A JP2022520471 A JP 2022520471A JP 2022520471 A JP2022520471 A JP 2022520471A JP 2022550458 A5 JP2022550458 A5 JP 2022550458A5
Authority
JP
Japan
Prior art keywords
compound
composition according
individual
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550458A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053642 external-priority patent/WO2021067506A1/en
Publication of JP2022550458A publication Critical patent/JP2022550458A/ja
Publication of JP2022550458A5 publication Critical patent/JP2022550458A5/ja
Pending legal-status Critical Current

Links

JP2022520471A 2019-10-01 2020-09-30 S1p1受容体に関連する状態を処置する方法 Pending JP2022550458A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
US62/909,113 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
JP2022550458A JP2022550458A (ja) 2022-12-01
JP2022550458A5 true JP2022550458A5 (cg-RX-API-DMAC7.html) 2023-10-10

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520471A Pending JP2022550458A (ja) 2019-10-01 2020-09-30 S1p1受容体に関連する状態を処置する方法

Country Status (12)

Country Link
US (1) US20220347158A1 (cg-RX-API-DMAC7.html)
EP (1) EP4037678A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022550458A (cg-RX-API-DMAC7.html)
KR (1) KR20220074913A (cg-RX-API-DMAC7.html)
CN (2) CN119280227A (cg-RX-API-DMAC7.html)
AU (1) AU2020360413A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005999A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156182A1 (cg-RX-API-DMAC7.html)
IL (1) IL291654A (cg-RX-API-DMAC7.html)
MX (1) MX2022003982A (cg-RX-API-DMAC7.html)
TW (1) TW202114656A (cg-RX-API-DMAC7.html)
WO (1) WO2021067506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023135506A1 (en) 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EP2528894A1 (en) * 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) * 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) * 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법

Similar Documents

Publication Publication Date Title
JP2022516662A5 (cg-RX-API-DMAC7.html)
CN101980704A (zh) 选择性s1p1受体激动剂的给药方案
EP4114466B1 (en) Treatment of pain and vasoconstriction
JP2018504398A5 (cg-RX-API-DMAC7.html)
JP2005506987A (ja) 感覚的に許容される口内崩壊性組成物
JP2022511788A5 (cg-RX-API-DMAC7.html)
JP2020531477A (ja) 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤
JP2022536623A (ja) 肺動脈性肺高血圧症の治療方法
JP2021500377A (ja) 遅延放出デフェリプロン錠剤及びその使用法
JP2022504181A5 (cg-RX-API-DMAC7.html)
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
JP2023509698A5 (cg-RX-API-DMAC7.html)
JP2023528896A5 (cg-RX-API-DMAC7.html)
JP2023531930A5 (cg-RX-API-DMAC7.html)
WO2006034631A1 (en) Composition comprising amlodipine and angiotensin ii receptor blocker
JP2024529084A (ja) 子宮内膜症を治療する方法及び有効な避妊を提供する方法
JPH10511097A (ja) 低薬用量リドグレル調合物および炎症性腸疾患の処置のためのそれらの使用
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
JP2002523363A (ja) 慢性疲労症候群および/または線維筋痛の処置のためのサブスタンスpアンタゴニストの使用および慢性疲労症候群の処置のためのnk−1レセプターアンタゴニストの使用
JP2003535897A (ja) アンギオテンシンiiアンタゴニストの新規使用法
JP2003523385A (ja) 神経変性疾患の治療法
JP2024532129A5 (cg-RX-API-DMAC7.html)
WO1996004917A1 (en) Remedy for myotonic dystrophy
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合